ClinicalTrials.gg
TerminatedNCT04141995Updated Nov 17, 2026Results posted

FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer

A Phase 2 interventional study of Digoxin and 5Fluorouracil in Pancreas Cancer and Adenocarcinoma of the Pancreas, sponsored by University of Nebraska. Terminated at 1 site in United States. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Nebraska · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
Due to low accrual and futility
Updated Nov 17, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 84 studies testing fluorouracil in Pancreatic Neoplasms — 11 open to participants now, 16 under way, 5 of them phase 3. Fluorouracil · Pancreatic Neoplasms.

Enrollment
69th of 76
11 · median 55
Started
2021
with 3 others
Phase 2
48 of 84
8 open now
Registered
67th of 84
by date

Among the 84 studies testing fluorouracil in Pancreatic Neoplasms, this one is the 69th largest by enrollment of the 76 interventional ones that give a count, is one of 4 that started in 2021, is one of 48 in phase 2, and was the 67th registered.

Pancreatic Neoplasms

3,903 studies on the registry are indexed under Pancreatic Neoplasms; 1,005 are open to participants now.

Browse Pancreatic Neoplasms studies →

Open to participants now

11 of the 84 studies testing fluorouracil in Pancreatic Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 743 Pancreatic Neoplasms studies recruiting now, 476 (64%) set no upper age limit and 153 (21%) stop at 75 or younger; 40 take children under 18; 60 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies testing fluorouracil in Pancreatic Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the feasibility and safety of combining digoxin as a modulator of the hypoxia pathway in combination with FOLinic acid, 5-Fluorouracil, IRINotecan and OXaliplatin (FOLFIRINOX) in participants with resectable pancreatic cancer.

Read the detailed description

Participants with resectable pancreatic cancer will be treated with oxaliplatin 85 mg/m² IV over 2 hours, irinotecan 150 mg/m² given concurrently with folinic acid 400 mg/m² IV over 90 min, followed by a 46-hour infusion of 5-fluorouracil 2400 mg/m². Slow oral digitalization will be used starting with a daily dose of 0.125 (participants over age 65) or 0.25 mg (participants 65 or younger) per mouth daily. A steady-state will be achieved after five half-lives, which is about 7 to 10 days in the average participant. The initial blood level will be obtained one week after starting digoxin. Assuming the digoxin level is at steady-state and the renal function is stable, there is a linear relationship between digoxin dose and serum concentration. The target digoxin level is between 0.8 to 1.2 ng/mL. Participants will receive IV chemotherapy at 2 week intervals. Re-staging imaging will be performed after 4 doses. If the participants has stable or responsive disease, an additional 4 doses will be given followed by re-staging imaging. The participant will then undergo surgical exploration \~ 4 weeks after the last dose of chemotherapy.

The primary endpoint is clinical toxicity. Other endpoints are status of pathologic margins, response rate, pathologic stage, progression-free survival, and overall survival. The correlative endpoint is baseline exome sequencing of circulating cell free tumor DNA. Measurement of quantity of circulating cell free tumor DNA at 4 week intervals while on chemotherapy and prior to surgery; resume at 3 month intervals after surgery. Genomic DNA will be collected at baseline for pharmacogenetic studies of polymorphisms that may be pertinent for the drugs used in the study. Blood will be collected for analysis of possible biomarkers of response to digoxin modulation.

03

Conditions studied

  • Pancreas Cancer
  • Adenocarcinoma of the Pancreas

Keywords

  • Resectable
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed pancreatic adenocarcinoma. Participants must have resectable disease with no evidence of distant .
  • 19 years of age or older.
  • (ECOG) Performance Scale (PS) of 0-1 (fully active to restricted in strenuous activity).
  • Chemotherapy for other than pancreatic cancer completed > 5 years ago and is no evidence of the prior malignancy at time of study entry.
  • Radiographically assessable disease.
  • Initial (ANC) greater than or equal to 1000/μL and count greater than or equal to 100,000/μL.
  • Normal serum potassium, magnesium and corrected calcium level.
  • Serum creatinine less than or equal to 2.0 mg/dL.
  • Total \<= 1.5 mg/dL [unless the participant has Gilbert disease with elevated non-conjugated (indirect) bilirubin; in such cases, the indirect bilirubin should be \<= 1.0 mg/dL].
  • If participant has biliary obstruction, biliary decompression will be required. Either endoscopic placement of biliary stent or percutaneous transhepatic drainage are acceptable. Once biliary drainage has been established, institution of FOLFOX therapy may proceed when the total bilirubin falls to \<= 5.0 mg/dL. The addition of irinotecan will be delayed until the total bilirubin is 1.5 mg/dL or lower.
  • Awareness of the neoplastic nature of his/her disease and willingly provide written, after being informed of the procedure to be followed, the experimental nature of the therapy, alternatives, potential benefits, side-effects, risks, and discomforts.
  • No prior chemotherapy for pancreatic cancer.

Exclusion criteria

Exclusion Criteria:

  • Unable to undergo staging laparoscopy, such as a prior history of multiple abdominal operations in which laparoscopy may not be technically feasible or might be potentially harmful.
  • A to receiving digoxin therapy (e.g., AV block, sick sinus syndrome, bradycardia, to digoxin or digitalis preparations).
  • Uncontrolled inter-current illness including, but not limited to ongoing or active infection requiring intravenous antibiotics, symptomatic congestive heart failure, unstable angina pectoris, or serious, uncontrolled cardiac arrhythmia, that might jeopardize the ability of the participant to receive the therapy in this study with reasonable safety.
  • Pregnant and nursing women (risk posed by chemotherapy agents). Female participants of must have a negative urine pregnancy test before receiving the first dose of study drug.
  • Prior except for adequately treated basal cell or squamous cell skin cancer, adequately treated non-invasive carcinomas, or other cancers from which the participant has been disease-free least 5 years.
  • Known infection or active or C infection (concern for increased toxicity).
  • Active disease [e.g., rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ulcerative colitis (UC), Crohn's Disease, multiple sclerosis (MS), ankylosing spondylitis (AS)].
  • Recognized acquired, hereditary, or congenital immunodeficiency disease including cellular immunodeficienciess, hypogammaglobulinemia, or dysgammaglobulinemia.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Treatment

    Participants start FOLFIRINOX. They will also begin digoxin and take it up to 4-5 months time period in patients with resectable pancreatic cancer. Digoxin is taken at the time of neo-adjuvant chemotherapy treatment, prior to surgery. After surgery, participants will continue with post-adjuvant chemotherapy.

    Drug: Digoxin · Drug: 5Fluorouracil · Drug: Calcium Leucovorin · Drug: Irinotecan · Drug: Oxaliplatin

Interventions

  • Tablet, Oral: Generic: 0.125 mg, 0.25 mg

    Also known as: Lanoxin, Digitek, Digox

  • DrugFluorouracilStudies of FluorouracilFluorouracil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    5-FU will be given as a 46 hour continuous IV infusion

    Also known as: Adrucil, 5-FU

  • DrugLeucovorinStudies of LeucovorinLeucovorin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    IV injection over 90 minutes

    Also known as: Folinic Acid

  • IV administration over 90 minutes

    Also known as: Camptothecin-11, CPT-11, Camptosar

  • IV administration

    Also known as: Eloxatin

06

What researchers measure

Primary outcomes

  1. Number of Patients Able to Undergo Resection Surgery

    Regimen will be considered for further investigation if 14 of the 20 patients are able to undergo resection

    Time frame: 16 weeks

Secondary outcomes

  1. Number of Subjects With Grade 4 Thrombocytopenia and Grade 3-4 Diarrhea

    Continuous monitoring will be performed to monitor toxicity using Pocock stopping boundary that yields the probability of crossing the boundary at most 0.05 when the toxicity rate is equal to 0.182 or 0.28 separately.

    Time frame: 16 weeks

07

Results

Posted Oct 21, 2026

Participant flow

Participant flow — Overall Study
MilestoneTreatment
Started11
Completed4
Not completed7

Outcome measures

PrimaryNumber of Patients Able to Undergo Resection Surgery

Regimen will be considered for further investigation if 14 of the 20 patients are able to undergo resection

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Number of Patients Able to Undergo Resection Surgery
ParticipantsTreatment
Number of Patients Able to Undergo Resection Surgery4
SecondaryNumber of Subjects With Grade 4 Thrombocytopenia and Grade 3-4 Diarrhea

Continuous monitoring will be performed to monitor toxicity using Pocock stopping boundary that yields the probability of crossing the boundary at most 0.05 when the toxicity rate is equal to 0.182 or 0.28 separately.

Time frame:
16 weeks
Reported as:
Number · participants
Number of Subjects With Grade 4 Thrombocytopenia and Grade 3-4 Diarrhea
participantsTreatment
Grade 3-4 Diarrhea1
Grade 4 Thrombocytopenia0

Adverse events

Collected over During the neoadjuvant/Digoxin treatment, AEs will be captured starting immediately after the patient has been administered the first dose of study drug(s) until 30 days following the last digoxin administration.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment0/7 (0%)1/7 (14.3%)7/7 (100%)
Most frequent serious events
Most frequent serious events
EventTreatment
Lymphocyte count decreasedInvestigations1/7
Blood bilirubin increasedInvestigations1/7
SepsisInfections and infestations1/7
Hepatobiliary Disorders-Other - Obstructed Biliary StentHepatobiliary disorders1/7
Hepatobiliary disorders-Other - CholangitisHepatobiliary disorders1/7
Most frequent other events
Showing 10 of 81
Most frequent other events
EventTreatment
AnemiaBlood and lymphatic system disorders7/7
FatigueGeneral disorders7/7
ParesthesiaNervous system disorders7/7
White blood cell decreasedInvestigations7/7
DiarrheaGastrointestinal disorders6/7
HyperglycemiaMetabolism and nutrition disorders6/7
HypokalemiaMetabolism and nutrition disorders6/7
HypomagnesemiaMetabolism and nutrition disorders6/7
Weight lossInvestigations6/7
Abdominal PainGastrointestinal disorders5/7

Baseline characteristics

11 participants were consented to this study. Four of those 11 were screenfails, thus did not start study. With 7 left, only 4 of those subjects completed the study and were evaluable for the primary outcome.

Age, Categorical
Age, Categorical(Participants)Treatment
<=18 years0
Between 18 and 65 years1
>=65 years6
Age, Continuous
Age, Continuous(Years)Treatment
Mean66.72 ± 10.85
Sex: Female, Male
Sex: Female, Male(Participants)Treatment
Female3
Male4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White7
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment
United States7
08

Study locations

1 site
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in May 2025, 51 months.

Results were first posted in Oct 2026, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2019
First posted
Oct 28, 2019
StartActual
Feb 12, 2021
Primary completionActual
May 13, 2025
CompletionActual
May 13, 2025
Results first posted
Oct 21, 2026
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted, then revised
posted Oct 21, 2026 · revised Nov 17, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedNumber of patients ablePatients Able to undergo resection surgeryUndergo Resection SurgeryTime frame: 16 weeks
Oct 21, 2026
Documents
Secondary outcomes
1 edited
What changed in the outcomes
  • EditedPercentageNumber of subjects with gradeSubjects With Grade 4 thrombocytopeniaThrombocytopenia and gradeGrade 3-4 diarrheaDiarrheaTime frame: 16 weeks
Oct 21, 2026
Show all 2 updates
  1. Nov 17, 2026
    Posted results revised
  2. Oct 21, 2026
    Results posted
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedNumber of patients ablePatients Able to undergo resection surgeryUndergo Resection SurgeryTime frame: 16 weeks
    Secondary outcomes 1 edited
    What changed in the outcomes
    • EditedPercentageNumber of subjects with gradeSubjects With Grade 4 thrombocytopeniaThrombocytopenia and gradeGrade 3-4 diarrheaDiarrheaTime frame: 16 weeks

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04141995
Responsible party
Sponsor
First posted
Oct 28, 2019
Start date
Feb 12, 2021
Primary completion
May 13, 2025
Completion
May 13, 2025
Results posted
Oct 21, 2026
Last update
Nov 17, 2026

Study contacts

Jean Grem, MD
principal investigator · University of Nebraska

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Digoxin · Fluorouracil · Leucovorin · Irinotecan · Oxaliplatin

Start the discussion